[Sustainability and new anticancer drugs]

Area of Science:

• Oncology
• Health Economics
• Public Health Policy

Background:

• Financial toxicity is an increasing concern affecting cancer treatment outcomes globally.
• The high cost of novel anticancer drugs poses a significant challenge to European healthcare systems, particularly those prioritizing equitable access.
• Current drug pricing may not align with the often marginal clinical benefits observed.

Purpose of the Study:

• To highlight the economic challenges posed by new cancer drugs in Europe.
• To advocate for regulatory strategies that incorporate economic evaluations in drug value assessment.

Main Methods:

• Review of current trends in anticancer drug pricing and healthcare system challenges.
• Analysis of the relationship between drug cost, efficacy, and clinical impact.
• Examination of policy implications for European regulatory bodies.

Main Results:

• The escalating cost of new anticancer therapies is straining European healthcare budgets.
• The clinical benefit of many new drugs is often marginal, questioning their cost-effectiveness.
• Existing data on financial toxicity in Europe is limited.

Conclusions:

• European regulatory frameworks require updating to include economic evaluations in drug approval and reimbursement decisions.
• A balanced approach considering both clinical efficacy and economic impact is crucial for sustainable cancer care.
• Addressing the financial toxicity of cancer treatment is essential for maintaining equitable access to care.